
Vaccibody announces collaboration to study VB10.16 and atezolizumab (Tecentriq®) in advanced cervical cancer 19 February 2019
Oslo, Norway, 13 February, 2019 Vaccibody AS, a clinical stage immuno-oncology company, announced today... Read more
Oslo, Norway, 13 February, 2019 Vaccibody AS, a clinical stage immuno-oncology company, announced today... Read more
Oslo, 14 February 2019 Reference is made to the press release by Vaccibody AS (“Vaccibody”... Read more
NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more
MinervaX, a privately held Danish biotech company, announces today that is has been awarded an in... Read more
This free ELIXIR Innovation and SME Forum with a focus on Genomics and Associated Data in Nationa... Read more
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical... Read more
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical... Read more
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Proceeds to fund Phase 2/3 trial of inhaled TD139 in idiopathic pulmonary fibrosis (IPF) and advancement... Read more